Table 3.
Clinical use | Method | Wavelength used | Affected by skin color | Ref. |
---|---|---|---|---|
Dermatological imaging | OCT | 1310 nm | Image quality may be reduced in patients with darker skin | 8 |
Treatment of AK | OCT | 1300 nm | Not discussed | 60 |
Treatment of AK | ALA-PDT | 410 to 420 nm | Not discussed | 61 |
Treatment of AK | PDT | Broadband daylight | Not discussed | 62 |
Treatment of BCC | MAL-PDT | Broadband (560 to 740 nm) | Not discussed | 63 |
Treatment of BCC | ALA-PDT | 410 to 420 nm | Not discussed | 61 |
Treatment of SCC | MAL-PDT | 630 nm | Not discussed | 61 |
Treatment of cutaneous T cell lymphoma—mycosis fungoides | MAL-PDT | 630 nm | Not discussed | 64 |
Treatment of acne | MAL-PDT | 630 nm | Regimen optimization required for different FSTs | 65 |
Treatment of BCC | Chlorin | 662 nm | Not discussed | 66 |
Treatment of melanoma | Chlorin | 662 nm | Not discussed | 67 |
Measurement of oxygen saturation | PO | 622 to 780 nm and 780 to 2400 nm | Darker skin tones are more likely to have overestimated oxygen saturation levels | 10 |
Heart rate sensing | PPG | 542 nm | Not discussed | 68 |